TABLE 1.

Susceptibilities of HIV-1_NL4-3 and HIV-2_ROD to nucleoside analogs

Straina	EC50 (μM)b
	AZT	ddI	d4T	PMPA	3TC	FTC	ABC
HIV-1NL4-3 (wt)	0.16 ± 0.07 (1)	4.7 ± 2.9 (1)	5.5 ± 1.6 (1)	7.2 ± 2.0 (1)	0.88 ± 0.29 (1)	0.27 ± 0.11 (1)	7.6 ± 3.0 (1)
HIV-1NL4-3 Q151M+4 variantc	7.0 ± 3.4 (43)	45 ± 17 (10)	79 ± 42 (14)	26 ± 11 (4)	3.7 ± 3.0 (4)	0.79 ± 0.10 (3)	40 ± 24 (5)
HIV-2ROD (wt)	0.12 ± 0.06 (1)	8.0 ± 5.5 (2)	7.1 ± 3.7 (1)	7.2 ± 3.8 (1)	2.0 ± 1.2 (2)	0.50 ± 0.14 (2)	7.2 ± 2.1 (1)

^aViruses produced with full-length plasmid clones of HIV-1_NL4-3 (pR9ΔApa) (23) or HIV-2_ROD (pROD9) (7). Infectivities of wild-type (wt) HIV-1_NL4-3 and the Q151M+4 variant of HIV-1_NL4-3 were 6,300 ± 2,000 and 4,500 ± 2,000 FFU/ng HIV-1 capsid p24, respectively (means ± standard errors of the means). The infectivity of wild-type HIV-2_ROD was 15 ± 9 FFU/ng HIV-2 capsid p26.

^bEC₅₀s were obtained with MAGIC-5A cells as previously described (22). The values shown in bold are significantly different from values for wild-type HIV-1_NL4-3 (P < 0.05; analysis of variance of log[EC₅₀] values by use of Tukey's multiple-comparison test). The numbers in parentheses indicate n-fold changes in the EC₅₀s relative to that for wild-type HIV-1_NL4-3. EC₅₀s are the means ± the standard deviations from four or more independent experiments. ddI, didanosine; d4T, stavudine; PMPA, tenofovir; ABC, abacavir.

^cMultinucleoside-resistant mutant (10).